A carregar...
A181 REAL-LIFE EFFICACY OF ELBASVIR/GRAZOPREVIR (EBV/GZV) FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1 AND 3 INFECTION
BACKGROUND: The introduction of all-oral direct acting antiviral (DAA) regimens has allowed for better tolerated, shorter, and more effective courses of therapy for HCV infection. Elbasvir (EBV, NS5A inhibitor) and grazoprevir (GZV, NS3/4A protease inhibitor) is a new fixed dose combination that has...
Na minha lista:
| Publicado no: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507925/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.182 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|